Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K1 | Q92918 | 14/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.47 |
| ▸ | ABL1 | P00519 | 1/20 | 0.47 |
| ▸ | PAICS | P22234 | 1/20 | 0.42 |
| ▸ | IKBKE | Q14164 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.42 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.40 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.40 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.39 |
| ▸ | MTOR | P42345 | 1/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | ATR | Q13535 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15283999 | 0.89 | IKBKE (0.41) | MAP4K1CYP3A4ABL1PAICSIKBKE | |
| SCHEMBL9280625 | 0.85 | IKBKE (0.46) | ABL1PAICSIKBKETBK1NTRK1 | |
| SCHEMBL15284003 | 0.84 | IKBKE (0.46) | ABL1PAICSIKBKETBK1NTRK1 | |
| SCHEMBL15284346 | 0.83 | PRKAB2 (0.46) | ABL1PAICSIKBKETBK1NTRK1 | |
| SCHEMBL9277430 | 0.82 | IKBKE (0.45) | ABL1PAICSIKBKETBK1NTRK1 | |
| SCHEMBL3720411 | 0.70 | MAP4K1 (0.54) | MAP4K1CYP3A4ABL1 | |
| SCHEMBL3723999 | 0.69 | MAP4K1 (0.56) | MAP4K1CYP3A4ABL1 | |
| SCHEMBL28668942 | 0.68 | FGFR3 (0.47) | — | |
| SCHEMBL9289123 | 0.68 | PDK2 (0.39) | ABL1IKBKETBK1NTRK1MET | |
| SCHEMBL9289026 | 0.68 | MAPT (0.41) | PAICSIKBKETBK1NTRK1MET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2646448-B1 | MACROCYCLIC KINASE INHIBITORS | OSI PHARMACEUTICALS LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9133224-B2 | Macrocyclic kinase inhibitors | OSI Pharmaceuticals, LLC (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2646448-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-09 | — | — | EP | disclosed |
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2013-10-03 | — | — | US | disclosed |
| WO-2012074951-A1 | MACROCYCLIC KINASE INHIBITORS | OSI Pharmaceuticals, LLC (US) | 2012-06-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130261086-A1 | MACROCYCLIC KINASE INHIBITORS | PTK2, SRC, PTK2B | MAP4K1 38/4885CYP3A4 2521/4885ABL1 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.